Download PDF

1. Company Snapshot

1.a. Company Description

Bionano Genomics, Inc.provides genome analysis software solutions.It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight.


The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics.In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes.The company was founded in 2003 and is headquartered in San Diego, California.

Show Full description

1.b. Last Insights on BNGO

Bionano Genomics' recent performance was negatively impacted by a series of challenging events. The company's decision to enter into a $10 million registered direct offering at a price of $0.252 per share, accompanied by warrants, may have diluted shareholder value. Additionally, the announcement of a reverse stock split, effective at a ratio of 1-for-60, could also have a negative impact on shareholder value. Furthermore, the company's debt restructuring, which defers amortization payments and reduces monthly payments from $1 million to $500,000, may not be sufficient to address its cash runway concerns. The absence of any recent earnings release makes it difficult to assess the company's current financial health.

1.c. Company Highlights

2. Bionano Genomics: Navigating a Margin‑Focused Growth Path

Fourth‑quarter revenue dipped 3% to $8.0 million, while full‑year sales fell 7% to $28.5 million, reflecting a modest decline in consumable volumes. Despite the revenue slide, Non‑GAAP gross margin improved to 43% in Q4 and 47% for the year, up from 35% in 2024, underscoring tighter cost control. Earnings slipped to a loss of $0.03 per share versus analysts’ $0.81 estimate, while the company’s valuation metrics sit at a P/S of 0.15 and EV/EBITDA of –0.34, indicating a heavily discounted market position. Staff noted that the strategic emphasis on routine‑use customers has begun to lift margins, a sentiment echoed in the guidance for 2026.

Publication Date: Apr -16

📋 Highlights
  • Revenue Decline and Margin Improvement: Q4 2025 revenue fell 3% to $8.0M, full-year revenue dropped 7% to $28.5M, but non-GAAP gross margin rose to 43% (Q4) and 47% (full-year).
  • Strategic Focus on Routine-Use Customers: High-volume clients account for 83% of OGM consumables revenue, with 130 routine-use customers as of 2025.
  • 2026 Revenue Guidance: Full-year 2026 revenue forecasted at $30–33M (5–16% growth), with Q1 guidance at $6.5–6.7M (flat to 3% growth over 2025).
  • Cash Position and Debt Retirement: Ended 2025 with $29.6M in cash and expects to retire senior secured convertible debt in May 2026, extending cash runway into 2027.
  • CPT Code Pricing Catalyst: Hematologic malignancy CPT code pricing increased 47% to $1,800 (from $1,200), effective January 1, 2026, expected to drive adoption and utilization.

Q4 2025 Performance

Revenue of $8.0 million, a 3% decline from $8.2 million in Q4 2024, was supported by the sale of 7,554 nanochannel array flow cells, slightly below the previous year’s volume. Gross margin rose to 43% from 42%, driven by higher mix of consumables and disciplined manufacturing costs. The company’s loss of $0.03 per share highlights the ongoing transition toward profitability.

Strategic Shift & Customer Focus

Bionano’s pivot to profitable growth centers on high‑volume “routine‑use” customers, who account for roughly 83% of consumables revenue. With 130 routine‑use accounts and 60 validated protocols, the firm is targeting steady sample throughput to stabilize cash flow. This focus aligns with the 47% margin increase seen in the year‑end, reinforcing the narrative that a narrowed customer base can drive profitability.

2026 Guidance & Market Catalysts

Guidance for 2026 projects $30–$33 million in revenue, a 5–16% top‑line increase over 2025, driven by new OGM systems and consumable sales at existing customers. The company expects flat to 3% growth in Q1 2026 revenue ($6.5–$6.7 million). A key catalyst is the 47% price increase for the hematologic malignancy CPT code, from $1,200 to $1,800, slated to boost adoption and utilization starting January 2026.

Financial Position & Debt Repayment

Cash and equivalents stood at $29.6 million, providing a runway into 2027. The senior secured convertible debt will be fully retired by May 2026, reducing leverage and improving the company’s financial flexibility. With a Net Debt/EBITDA of –0.17, Bionano is positioned to fund growth without additional borrowing.

Valuation Outlook

At a P/S of 0.15 and EV/EBITDA of –0.34, the stock trades at a steep discount relative to peers, reflecting the market’s current skepticism about margin turnaround. However, the company’s improving gross margin and strategic focus on routine‑use customers could justify a re‑valuation, especially if 2026 revenue growth aligns with the upper end of guidance and the CPT code price lift accelerates consumable sales.

3. NewsRoom

Card image cap

Bionano Announces Publication from Johns Hopkins and MD Anderson Showing that OGM can Outperform Traditional Methods in Analysis of Multiple Myeloma

Apr -02

Source: globenewswire.com

Card image cap

Bionano Genomics, Inc. (BNGO) Q4 2025 Earnings Call Transcript

Mar -23

Source: seekingalpha.com

Card image cap

Bionano Genomics Stock Soars As Efficiency Gains Meet Growth Story

Mar -23

Source: benzinga.com

Card image cap

Bionano Reports Fourth Quarter and Full-Year 2025 Results and Provides Revenue Outlook for 2026

Mar -23

Source: globenewswire.com

Card image cap

Bionano Genomics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Mar -20

Source: benzinga.com

Card image cap

Bionano Genomics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Mar -20

Source: feeds.benzinga.com

Card image cap

Bionano Genomics (BNGO) Projected to Post Quarterly Earnings on Monday

Mar -16

Source: defenseworld.net

Card image cap

Bionano to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call Webcast on March 23, 2026

Mar -09

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.54%)

6. Segments

Consumables

Expected Growth: 10.43%

Bionano Genomics' Consumables segment growth of 10.43% is driven by increasing adoption of optical genome mapping in genetic disorder diagnosis, rising demand for non-invasive prenatal testing, and growing use of precision medicine in cancer treatment, coupled with expanding global distribution channels and strategic partnerships.

Instruments

Expected Growth: 10.47%

Bionano Genomics, Inc.'s 10.47% growth is driven by increasing adoption of its Saphyr system for optical genome mapping, strong sales of its NanoChannel arrays, and growing demand for its genome analysis services. Additionally, the company's expanding partnerships with leading research institutions and pharmaceutical companies, as well as its increasing presence in the liquid biopsy market, contribute to its growth momentum.

Services and Other

Expected Growth: 10.95%

Bionano Genomics' Services and Other segment growth of 10.95% is driven by increasing adoption of its genome analysis services, expansion of its customer base, and growing demand for its proprietary Saphyr system. Additionally, the company's strategic partnerships and collaborations have contributed to the growth, as well as its focus on providing high-quality services and support to its customers.

Software

Expected Growth: 10.27%

Bionano Genomics' software growth is driven by increasing adoption in genomics research, precision medicine, and clinical diagnostics. The company's optical genome mapping technology provides a unique value proposition, enabling researchers to better understand genome structure and function. Growing demand for genomic analysis, partnerships with leading research institutions, and expanding sales channels contribute to the 10.27% growth rate.

7. Detailed Products

Saphyr

A high-resolution, high-throughput genome mapping instrument that enables the analysis of ultra-long-range genomic information

Irys

A high-resolution, high-throughput genome mapping instrument that enables the analysis of ultra-long-range genomic information

Bionano Prep

A DNA labeling and staining kit used to prepare high-molecular-weight DNA for genome mapping

Bionano Access

A cloud-based software platform that enables users to analyze and interpret genome mapping data

Bionano Solve

A software tool that enables users to analyze and interpret genome mapping data

8. Bionano Genomics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bionano Genomics, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing development of new technologies.

Bargaining Power Of Customers

Bionano Genomics, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are highly specialized, making it difficult for customers to switch to alternative suppliers.

Bargaining Power Of Suppliers

Bionano Genomics, Inc. relies on a limited number of suppliers for its raw materials and components. While the company has some bargaining power due to its size, suppliers may still exert some pressure on prices and delivery terms.

Threat Of New Entrants

The biotechnology industry has high barriers to entry, including significant capital requirements, complex regulatory requirements, and the need for specialized expertise. These barriers make it difficult for new entrants to compete with established companies like Bionano Genomics, Inc.

Intensity Of Rivalry

The biotechnology industry is highly competitive, with many established companies competing for market share. Bionano Genomics, Inc. faces intense competition from companies with similar products and technologies, which can lead to pricing pressure and reduced market share.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 47.77%
Debt Cost 5.82%
Equity Weight 52.23%
Equity Cost 16.02%
WACC 11.15%
Leverage 91.46%

11. Quality Control: Bionano Genomics, Inc. passed 1 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Personalis

A-Score: 3.9/10

Value: 6.4

Growth: 3.1

Quality: 3.7

Yield: 0.0

Momentum: 9.5

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
VolitionRx

A-Score: 3.7/10

Value: 8.0

Growth: 6.3

Quality: 5.8

Yield: 0.0

Momentum: 1.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Bionano Genomics

A-Score: 3.3/10

Value: 10.0

Growth: 4.3

Quality: 4.0

Yield: 0.0

Momentum: 0.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
T2 Biosystems

A-Score: 3.2/10

Value: 10.0

Growth: 4.7

Quality: 4.8

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Aclaris Therapeutics

A-Score: 3.2/10

Value: 6.7

Growth: 6.7

Quality: 4.0

Yield: 0.0

Momentum: 0.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Inotiv

A-Score: 2.8/10

Value: 9.0

Growth: 3.1

Quality: 2.1

Yield: 0.0

Momentum: 2.0

Volatility: 0.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

1.29$

Current Price

1.29$

Potential

-0.00%

Expected Cash-Flows